投稿一覧に戻る
(株)ジーエヌアイグループ【2160】の掲示板 2024/05/09〜2024/05/11
-
404
>>395
Generated sales of $26.9 million in Q1 of 2024. For the quarter ended March 31, 2024, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals), Gyre’s majority indirectly owned subsidiary in the People's Republic of China (“PRC”), generated $26.9 million in sales of ETUARY, representing an increase of 10% from the same period in 2023, driven by enhanced marketing and sales initiatives in regions of the PRC where sales were previously lower in the first quarter of fiscal year 2023.
円建てで4,035百万円程度かな？アイスだけで前期Q1の売上4,206百万円超えるね。グニちゃんて、医薬品とかセグメント別売上しか出してなかったよね？これはグニちゃんのQ1も計算できるぞ。
伍味太輔
>>389
U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025
IND申請は2024年なんだね。